- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
Hayden and Teplow review molecular and cell biology insights from in vivo, in vitro and in silico studies of amyloid β-protein (Aβ) oligomers, and limitations to be considered in these results.
Amyloid-beta42 lowering drug, flurbiprofen, successfully crossed an in vivo blood-brain-barrier model and lowered amyloid-beta42 generation when embedded in polylactide nanoparticles; a promising tool to facilitate drug delivery to the brain.
Souvenaid, a medical drink designed to support synapse synthesis in people with Alzheimer's disease (AD), did not slow cognitive decline in people with mild-to-moderate AD in a 24-week study.
Novel measures and questionnaires are being explored to detect cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals; Rentz and colleagues review a selection of some potentially promising approaches.
Gustafson and Luchsinger debate epidemiologic evidence for and against an association between higher adiposity and Alzheimer's disease (AD), and discuss potential biological mechanisms for the observed associations and explanations for conflicting evidence.
Editor-in-Chief Philip Scheltens reviews the monoclonal antibodies designed to clear toxic amyloid-beta from the brain, and discusses what can be learnt from the results of recent phase 3 clinical trials.
Calmodulin levels significantly increased in Alzheimer's disease (AD) peripheral cells, but not in other neurodegenerative disorders, indicating use as a potential biomarker for mild-AD and in differentiating from other types of dementia.
Bart De Strooper comments on the recent bexarotene controversy in the Alzheimer's disease (AD) field, examining available data and questioning what we can learn from the experiments to aid future developments.
Latest free review
The following review has recently become free to access:
Leonel T Takada, Sharon J ShaAlzheimer's Research & Therapy 2012, 4:38 (3 October 2012)
News from Alzforum
From the blog
- 18 November 2013
- Does being overweight increase the risk of dementia?
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.
Volume 5 Suppl 1 (8 July 2013)
Background documents to the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4)
Montreal, Canada. 4 May 2012